Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

AUM Biosciences

Founded by 2 ex-Quintiles (Now IQVIA) and industry veterans, AUM Biosciences is an oncology-focused biotechnology company headquartered in Singapore that develops innovative and affordable medicines for patients in Asia and globally.

The founders and the management team have over 75 years of combined oncology drug development experience, and track record of developing and executing various virtual drug development models in the Industry. AUM’s pipeline includes a novel, small molecule targeted therapy which has the potential to address high unmet medical needs in various solid and liquid tumours. Additionally, it has an undisclosed pipeline of additional pre-clinical and phase I ready programs. Pipeline focus is on small molecules targeted therapies with a mandate of clear biomarker driven strategies for every asset in the pipeline. AUM harnesses the power of precision medicine and digital technologies to accelerate the drug development timelines to unlock the value of innovation.

  • Date:Monday, February 11
  • Time:1:30 PM - 1:45 PM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23359
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Investor Outreach
  • Company Website:www.aumbiosciences.com
  • Company HQ City:Singapore
  • Company HQ Country:Singapore
  • Total Amount Raised to Date, in All Rounds:2M
  • Year Founded:2018
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:MnK 1/2 Inhibitor
  • Development Phase of Primary Product:Phase I
  • Additional Information/Comments:AUM has global rights to develop, commercialize and manufacture in all indications. Drug was discovered and developed through a collaboration between A*STAR’s Experimental Therapeutics Centre (ETC) and Duke-NUS Medical School (a partnership between Duke University School of Medicine and the National University of Singapore). It advanced into first-in-man trials in December 2016. Initial clinical studies suggest that the drug is very well tolerated and could be used as a thera∂ßpy across a range of liquid and solid tumor types. The drug promises a more targeted approach by inhibiting the Mnk enzyme in cancer cells, which is a key player in promoting cancer growth when activated. The competitive analysis showcases that the drug has only one immediate publicly available competitor in development.
Speakers
Vishal Doshi, B.Pharm, MSc
AUM Biosciences
Back